News Hub | News Direct

Cellular Goods provides update on King Tide Carbon integration

Cellular Goods PLC

Cellular Goods PLC (LSE:CBX) chairman and interim CEO Darcy Taylor speaks to Thomas Warner from Proactive about how the acquisition of biosynthetic algae & seaweed carbon sequestration as-a-service company King Tide Carbon (KTC) has been proceeding since it completed back in May. Taylor says that the acquisition of King Tide Carbon has allowed Cellular Goods to expand its vision of sustainability and capitalise on the increasing demand for carbon removal solutions driven by the Paris Climate Agreement. He goes on to emphasise the importance of bio-synthetics as an emerging technology for carbon removal and highlighted the expertise of the King Tide team in accelerating the company's direction. With the acquisition, Cellular Goods aims to be at the forefront of scalable and high-quality carbon removal solutions, contributing to the fight against climate change while delivering value to shareholders. He also addresses how long he is likely to stay in the interim CEO role, saying that his main priority is to deliver growth and development for the business and that he "remains committed for the next twelve months and beyond." He also commits to providing more frequent updates to shareholders. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 12, 2023 06:16 AM Eastern Daylight Time

Video

Mechelle Evans Announces GlowByMe, Her New Skincare Company

Client Valley

Las Vegas, NV - Mechelle Evans, the founder of GLO by ME SKIN, is pleased to announce her new company dedicated to revolutionizing the skincare industry. With a focus on providing excellent services and education, Mechelle is transforming the way individuals care for their skin. Mechelle, an esteemed Aesthetician, believes that healthy and glowing skin is a birthright for everyone. Recognizing the skin as the body's largest organ, she emphasizes the importance of proper skincare. Through a comprehensive range of services, Mechelle helps her clients achieve their skin goals, whether it's combating acne, reducing wrinkles, or maintaining overall skin health. However, Mechelle's mission extends beyond offering services; she is dedicated to educating individuals about the significance of skincare. She emphasizes the harmful effects of UV rays and environmental pollutants on the skin, which can lead to premature aging and other skin conditions. By instilling the importance of regular facials, proper cleansing, and the use of high-quality products, Mechelle empowers her clients to protect and enhance their skin's health. Mechelle's journey into skincare began in the early 1990s when she worked as a television extra. Witnessing the damage caused by heavy makeup and sun exposure, she became determined to maintain her own skin's health. Her introduction to Dr. Obagi, a renowned skincare expert, solidified her belief in the transformative power of skincare, prompting her to further educate herself on the subject. Motivated by her passion for helping others achieve clear and healthy skin, Mechelle made the life-changing decision to become a full-time aesthetician. Despite leaving behind a six-figure salary, she was driven by a greater purpose. Mechelle aimed to make a lasting impact on people's lives and be remembered for making a real difference. As an advanced licensed professional specializing in melanated skin, Mechelle offers a wide range of services, personalized skincare recommendations, and advanced treatments like chemical peels, microneedling, and lasers. Her goal is to provide effective solutions tailored to diverse skin tones, challenging prevailing mindsets that discourage treatment for such skin types. Driven by her dedication to delivering results, Mechelle embarked on creating her own skincare line. Her flagship product, a 1% retinol, stands out for its ability to address multiple skin types and deliver exceptional results. Infused with powerful antioxidants, essential amino acids, minerals, and botanical moisturizers, this retinol promotes healthy cell regeneration and collagen production, resulting in reduced visible signs of aging, diminished pores, and blemishes. Through GLO by ME SKIN, Mechelle Evans is redefining skincare by combining the power of education, quality treatments, and effective products. With her advanced knowledge, personalized approach, and commitment to inclusivity, she has become a trusted advisor and advocate for skin health. In a world where healthy skin is highly valued, Mechelle's vision of empowering individuals to embrace their natural beauty and achieve a healthy complexion is becoming a reality. Her expertise, passion, and transformative results have earned her a reputation as a leading force in the skincare industry. As Mechelle continues to leave her mark on the field, her dedication and expertise are changing lives. Through GLO by ME SKIN, she is making a genuine difference, leaving a lasting legacy as someone who revolutionized skincare and helped individuals achieve radiant, healthy skin. About Mechelle Evans: Mechelle Evans is the founder of GLO by ME SKIN, a skincare brand dedicated to providing innovative and effective skincare solutions. With a passion for skincare and a commitment to education, Mechelle offers personalized services and products to help individuals achieve healthy and radiant skin. Her expertise and transformative results have earned her recognition as a trusted advisor in the skincare industry. Contact Details GLO by ME SKIN Crissy Henry office@9figuremedia.com Company Website http://www.globyme.com/

July 11, 2023 05:24 PM Eastern Daylight Time

Image

Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. NanoViricides (NYSE American: NNVC) has begun trials for its new drug candidate, NV-CoV-2 — an exciting development for the biotech company, as it starts its first human trials with drug sponsor Karveer Meditech Pvt. Ltd. India, the company’s licensee and co-developer in India. NanoViricides has been building out a novel nanomedicine platform for many years, and this platform now includes a pipeline of multiple preclinical antiviral drugs. The Company is developing antiviral medications that are built on the company’s patented nanoviricide technology. Nanomedicine has a lot of promise, but there are almost no nanomedicines available on the market to treat viral infections. Because of prior acquired expertise, NanoViricides’ first-in-class COVID drug, NV-CoV-2, took just about one year to complete IND-enabling studies, from the discovery stage in January 2020. As a small company with a novel mechanism implemented using out-of-the-box technologies, it took the Company much longer time to actually start clinical trials. Now that it has this regulatory experience, additional drug developments should not take such a long lag time. “We believe these clinical trials are an important milestone not only for NanoViricides and Karveer Meditech, India, but also for the advancement of treatments against all viral infections worldwide,” said Dr. Anil Diwan, President and Executive Chairman of NanoViricides. NanoViricides’ Treatment Of Coronaviruses The company’s first drug candidate is NV-CoV-2, a broad-spectrum, anti-coronavirus treatment. Other companies have developed treatments for COVID-19, These include Molnupiravir from Merck & Co. (NYSE: MRK), Paxlovid from Pfizer Inc. (NYSE: PFE) and Remdesivir from Gilead Sciences, Inc. (NASDAQ: GILD). However, there are limitations or drawbacks to each of these treatments. As a broad-spectrum anti-coronavirus drug, NV-CoV-2 has been shown to work against a variety of unrelated coronaviruses. This suggests that different strains or mutations are unlikely to escape the drug. Several common coronavirus strains include hCoV-229E, hCoV-OC43, hCoV-HKU1, and hCoV-NL63, which recur seasonally. Of these, NL63 and OC43 present with pneumonia similar to the delta COVID variant in susceptible patients, leading to fatalities at rates that are comparable to seasonal influenza. Now, SARS-CoV-2 with its variants is added to this list as a commonly occurring coronavirus. A Nanomedicine Platform For Other Viruses The trials for NV-CoV-2 are part of the company’s development of a novel platform technology employing nanoviricides. The NV-CoV-2 drug contains NV-387, a first-in-class chemical nanomedicine, and its unique mechanism of action (MoA) doesn’t rely on the patient’s immune system to destroy the virus. The Company says that NV-387 mimics an attachment receptor family to which over 90% of known viruses bind, and NanoViricides hopes that NV-387 will likely be a clinically effective drug against at least a few of these viruses. The Company has said that it has begun R&D work to expand the indications of NV-387 to other viruses. By bringing NV-CoV-2 to human trial, NanoViricides has demonstrated the platform’s capability to deliver a clinically relevant antiviral. After the Phase 1 studies are completed, the safety and tolerability data will be applicable to any other viruses that the Company targets using NV-CoV-2, assuming it can demonstrate pre-clinical success. Then NV-387 can directly enter Phase 2 as an antiviral against such additional viruses — which would likely mean significant cost and time savings for the additional indications, and substantial improvement in the return on investment (ROI) for the Company with commensurate benefits to the investors. The Company is not a “one-trick pony” either. It already has NV-HHV-1, a drug to treat shingles rashes, that has completed pre-clinical studies. The company believes its platform could provide treatments for a host of viruses, including other herpesviruses (cold sores, genital ulcers, and many other serious diseases), as well as influenza and HIV. This would position NanoViricides at the intersection of multiple growing treatment markets. The herpes treatment market was worth $1.5 billion in 2022 and is predicted to grow at a compound annual growth rate (CAGR) of 9.2% over the next seven years. The influenza market is expected to reach $1.2 billion by 2026, while the HIV market is predicted to reach $36 billion by 2027. For now, however, the company is keeping laser-focus on the development of NV-CoV-2 for treating COVID-19 and long COVID. Its current trial will test the drug’s safety and efficacy, and the data will be used to prepare for phase 2 trials. “NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations,” said Diwan. “Moreover, it brings into the clinic a novel platform technology of attacking viruses to develop highly effective antiviral drugs.” Learn more about how NanoViricides is tackling different viruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 11, 2023 09:25 AM Eastern Daylight Time

Fawn River Cultivation Company and BioLumic Unleash a New Era of Cannabis Varieties in Michigan

BioLumic

Fawn River Cultivation Company and BioLumic announced today a new partnership to redefine cannabis cultivation in Michigan using BioLumic’s patented UV light technology, opening the door for new varieties to hit the consumer market by the end of 2023. “The BioLumic technology will enable the creation of varieties with unique wellness benefits and extraordinary experiences,” said John Babcock, CEO, Fawn River Cultivation Company. “Michigan consumers deserve more varieties with a greater value at every price point. In addition to curating best-in-class genetics to expand our product line, we look for innovative partners like BioLumic to help us meet the quickly changing market.” Now the nation’s second-largest cannabis market, the state of Michigan has positioned itself as a national leader in the cannabis industry. Fawn River services approximately 100 provisioning centers in the Michigan cannabis market with two retail locations in the Great Lake State. Through this partnership, Fawn River will deploy BioLumic’s propagation-stage light recipes to regulate cannabinoids and terpenes profiles to develop a wider and more compelling range of consumer products and consumer wellness benefits. “Fawn River is a vertically-integrated cannabis company with a state-of-the-art cultivation facility, experienced team and a true understanding of what the Michigan cannabis consumer values in its varieties,” said Steve Sibulkin, CEO, BioLumic. “This partnership has the potential to redefine cannabis market dynamics in Michigan by ushering in a new era of products and product development.” Built on two decades of plant science, BioLumic’s UV Light Signal Recipe™ platform is based on the established science of photomorphogenesis – the ability to regulate the genetic expression of plants with light. It combines plant genetic insights, wide-ranging plant response data and a software and hardware platform that can deploy trillions of short-duration ‘light recipes.’ BioLumic’s Light Recipes™ are a targeted, programmed sequence of light spectrum exposure which activate positive growth responses in seeds and young plants. “The proprietary nature of the BioLumic light treatment pairings ensures defensible gains in an industry marked by quick-changing demands,” said Babcock. “It also allows us to go beyond cultivating top strains alone to create ongoing advantages that not only sets Fawn River apart in the industry but continue to improve our offering to consumers at an unbelievable pace.” To learn more, visit biolumic.com or fawnrivercc.com. About BioLumic: Founded in 2013, BioLumic is a New Zealand and U.S.-based agricultural biotech company that programs plants and seeds with light to unlock growth, quality and health. The company's Light Signal Recipe™ platform combines biological data, plant science, and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. BioLumic's Light Treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. Contact us at www.biolumic.com or email to info@biolumic.com. About Fawn River Cultivation Company: Fawn River Cultivation Company is a vertically integrated seed to sale cannabis company headquartered in Constantine, Michigan. Our focus is to cultivate and provide only the highest quality cannabis flower and premium products while offering world class customer service to our customers. Fawn River Cultivation Company strives to build a trusted brand that honors the cannabis plant as a part of a comprehensive approach to health. Contact Details BioLumic Nicole Prenger nicole@agtechpr.com Fawn River Cultivation Company Jennifer Babcock jrbabcock@fawnrivercc.com Company Website https://www.biolumic.com

July 11, 2023 08:00 AM Central Daylight Time

Image

Scancell Holdings "well-financed" and continuing to pursue deals

Scancell Holdings PLC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the clinical stage biopharmaceutical company's progress and financial position. Durrant starts by highlighting that Scancell has "plenty of money" before going into more detail about what's been happening with its two lead compounds, SCIB1 and Modi-1. She also touches on progress in the relationship with Genmab since signing a commercial licensing agreement last year, and clarifies that Scancell is continuing to pursue other such deals: "We've just signed an evaluation with a new company... and we're in current discussions with a second company about another potential deal." She adds that the company is "well financed" with a runway extending into the second half of 2024, but makes it clear that the continued emergence of promising clinical data could make a fundraise necessary - saying that "clearly a company of our size always needs to think about that as we go forward." Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 11, 2023 06:51 AM Eastern Daylight Time

Video

MGC Pharmaceuticals "pushing on" after announcing fresh $1mln order

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Thomas Warner from Proactive after the Europe-based plant-inspired medicine company announced it has secured a US$1mln order from AMC Pharma for ArtemiC, an anti-inflammatory that is also shown to provide benefits to Covid sufferers. Clements gives an overview of the order and of the ArtemiC product, explaining that its "the OTC form of CimetrA, which is under development as an FDA new drug indication file." In March 2023, MGC Pharma revealed that ArtemiC had gained a spot on the National Drug Code Database as an OTC Unlicensed Drug, approved by the US FDA. Clements says that "we are pushing on as fast as we can and I think you'll hear more good news about some aspects of one or more of those products in the weeks and months ahead." MGC Pharmaceuticals says on its website that ArtemiC has been tested for safety and efficacy in a double-blind, placebo-controlled clinical trial of 50 patients diagnosed with COVID-19. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 11, 2023 06:23 AM Eastern Daylight Time

Video

News Release

Sibannac aims to become a pioneer in next-generation wellness

Sibannac Inc

Sibannac Inc CEO David Mersky joined Chris Rhodes from Proactive with the latest developments within the company. Sibannac, or cannabis spelled backwards, is creating and selling premium next-generation wellness products in the consumer packaged goods space, with a particular emphasis on the cannabis industry. Mersky highlighted that Sibannac's subsidiary, Immersive Brand Concepts, based in Oklahoma City, has recently introduced its newest product line called "Let's Go Health and Immunity." This product line features a diverse range of health and immune-boosting products that have been formulated using natural elements such as Fulvic Acid, Humic Acid, Zinc, Vitamin D, and Silver. Mersky also discussed Sibannac's involvement with Kratom and expressed the company's ambition to be a pioneer in its use. By focusing on innovative formulations and leveraging natural elements, Sibannac aims to position itself at the forefront of the wellness industry. Through their Let's Go Health and Immunity product line and their exploration of Kratom, Sibannac strives to provide unique and cutting-edge solutions for consumers seeking premium wellness products. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

July 07, 2023 03:53 PM Eastern Daylight Time

Video

HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate — Could Longeveron’s Lomecel-B Improve Outcomes?

LONGEVERON INC.

By David Willey, Benzinga Longeveron (NASDAQ: LGVN) announced the results of its phase 1 trial for infants with a rare and serious congenital heart disease (CHD), known as hypoplastic left heart syndrome. The Company, which is now conducting its phase 2a trial, is a clinical-stage biotechnology firm working to develop treatments for rare diseases and age-related and life-threatening conditions. CHDs are the most common congenital disease, affecting around 40,000 babies born in the U.S. every year. While many CHDs can be medically managed, 25% are much more serious and often require immediate surgical intervention. As a result, CHDs are a leading cause of death for infants. An increase in critical CHDs is powering growth in the newborn screening market, which is expected to reach $3 billion in 2031, growing at a compound annual growth rate (CAGR) of 11.2% from 2021 to 2031. Longeveron is working to develop a treatment for one of the most severe CHDs, hypoplastic left heart syndrome (HLHS). HLHS is a very serious heart defect in which the left side of the heart is underdeveloped and unable to provide normal blood circulation through the heart. HLHS accounts for 2-3% of all CHDs, with around 1 in every 3,800 US babies being born with HLHS every year. HLHS is considered a rare pediatric disease, and Longeveron has received a Rare Pediatric Disease Designation from the FDA for Lomecel-B. Children with HLHS require 3 different open-heart surgeries to allow survival, but even with these surgeries, many of the children will go on to need a heart transplant. Despite the increasing sophistication of these surgeries, the neonatal death rate for HLHS is 33%, and the 5-year survival rate is only 50-60%. HLHS treatments are also expensive, costing the average neonatal hospital stay over $280,000. Longeveron Completes Phase 1, Starts Phase 2 Longeveron is focusing on HLHS with its cell-based therapy, the drug candidate, Lomecel-B ™. This drug, which is made from medicinal signaling cells (MSCs), will be a potential combinational therapy delivered via intracardiac injection during the second neonatal open-heart surgery. The goal of adding Lomecel-B ™ is to boost the function of the single ventricle, with the ultimate goal of reducing the need for transplantation and possibly increasing survival. The Company concluded its open-label phase 1 trial on 10 patients, aged four to five months, and followed these children for a period ranging from 3.5-5 years. The one-year trial’s results were published in the European Heart Journal Open, and revealed that all the patients had responded well to the procedure and were transplant-free one year after the treatment. None of the babies experienced a pre-defined safety endpoint, and the procedure was well tolerated. “This data supports our hope that Lomecel-B TM has the potential to alter the treatment landscape for patients with HLHS, a rare and life-threatening congenital heart disease,” said Wa’el Hashad, Longeveron’s Chief Executive Officer. “Notably, the procedure appeared to be generally safe and well-tolerated in the babies undergoing heart surgery in the first 6 months of life. The study provisionally shows suggestions of possible improvement in measures of cardiac function, findings that are presently being tested in our ongoing controlled and randomized Phase 2 study.” Dr. Joshua Hare, who co-authored the European Heart article, is the co-founder of Longeveron and is an established leader in the field of cardiac treatment. He recently published a second article on HLHS, which described the current status of treatments for HLHS and outlined the future direction of the field. The article identifies Lomecel-B ™ as the first-in-class MSC therapy to reach the trial stage. Longeveron is moving forward with its phase 2 trial in partnership with the National Heart, Lung, and Blood Institute and the trial is being conducted at 8 leading pediatric cardiac surgical programs. This randomized, blind, controlled study with 38 patients will evaluate Lomecel-B’s ™ intracardiac injection for both safety and efficacy. Future positive results could position Longeveron as a leader in the field, with the hope of saving the lives of many infants through this novel therapy. Keep up to date with Longeveron’s cell-based therapies on its website www.longeveron.com. We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 844-470-2550 christine@tradigitalir.com Company Website https://longeveron.com/

July 07, 2023 09:00 AM Eastern Daylight Time

RDW Group Recognized with Three Industry Bell Ringer Awards

RDW Group

RDW Group is proud to announce it has won three Bell Ringer Awards for exemplary PR, communications, and marketing work completed in the last year. Each year, the PR Club hosts the Bell Ringer Awards Ceremony to celebrate outstanding work conducted by industry professionals, agencies, and in-house teams throughout the New England region. The 2023 awards ceremony was held on Thursday, June 8 at the Royal Sonesta Boston. During the event, RDW was recognized for its work with multiple clients and across multiple categories, including: Silver Bell – Healthcare Campaign, “Substance Exposed Newborns Awareness and Provider Outreach” with the Rhode Island Department of Health Silver Bell – Integrated Marketing Communications Campaign, “It Happens Right Here” with Rhode Island PBS Merit award – Integrated Marketing Communications Campaign, “Recycle PVD” with Rhode Island Resource Recovery Corporation “Winning a Bell Ringer Award signifies one of the highest levels of achievements for New England communicators,” said Sofia Giovannello, PR Club president and managing supervisor of Methods+Mastery. “Year after year, we see incredible work reflected in the quality of entries. On behalf of everyone at PR Club, we congratulate all the winners!” "RDW is once again proud to represent each of our clients in the 55 th annual Bell Ringers Awards,” said Phil Loscoe, Jr., managing partner of RDW Group. “It is their drive and dedication to make our world a better place – through healthcare, education and culture, and environmental stewardship – which brings these campaigns to life and ultimately drives positive change. Congratulations to our client teams and RDW internal teams on their continued work and success. Very well deserved.” View the full list of all 2023 award recipients here. About RDW Group, Inc. Founded in 1986, RDW Group is a full-service agency offering advertising, public relations, digital marketing, and media services based in Providence, R.I. RDW also operates iFactory, an award-winning web strategy, design and development group based in Boston. More info at www.rdwgroup.com. About PR Club Founded in 1948, PR Club (formerly the Publicity Club of New England) strives to promote and encourage involvement in the communications industry and specifically the professions of public relations, promotions, and marketing. Get additional information about monthly PR Club programs, social and networking events, the “Bell Ringer” blog, and the Bell Ringer Awards Ceremony at www.prclub.org. Follow them on Twitter @PRClubofNE. Founded in 1986, RDW Group is a full-service agency offering advertising, public relations, digital marketing, and media services based in Providence, R.I. RDW also operates iFactory, an award-winning web strategy, design and development group based in Boston. More info at www.rdwgroup.com. Contact Details Michael Masseur +1 401-521-2700 mmasseur@rdwgroup.com Company Website https://rdwgroup.com

July 06, 2023 09:30 AM Eastern Daylight Time